SLC6A2 and major depressive disorder: Quetiapine’s properties as a partial agonist of 5-HT1A and as a potent inhibitor of norepinephrine transporter through its metabolite seem to partly explain the mechanism of major depressive disorder treatment (Cross et al., 2016).